MIM
CINC

Monashee Investment Management’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Monashee Investment Management’s Portfolio CINC Stock Details CINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,000
Closed -$985K – 73
2022
Q3 		$985K Buy
+30,000
New +$848K 0.37% 38

Other funds holding CINC

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Monashee Investment Management's CINC Position: Q4 2022 in Review

Monashee Investment Management sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q4 2022, closing a stake of 30,000 shares — an estimated $985K sold.

Monashee Investment Management first reported a position in CINC in Q3 2022 and held it in 1 quarter. The position peaked at $985K in Q3 2022. 102 funds tracked by Wall St. Rank hold CINC as of Q4 2022.

  • Monashee Investment Management reported no remaining CinCor Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Monashee Investment Management sold 30,000 CinCor Pharma, Inc. Common Stock shares in Q4 2022, an estimated $985K.
  • Monashee Investment Management first reported a position in CinCor Pharma, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Monashee Investment Management's CinCor Pharma, Inc. Common Stock position peaked at $985K in Q3 2022.
  • 102 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q4 2022.

Based on Monashee Investment Management's 13F filing for Q4 2022, filed 9 Feb 2023.